Loading ......
Filter By Product Search for
ATN1
ATN1 Full Name
atrophin 1
ATN1 Introduction
Atrophin-1 (ATN1) is a transcriptional coregulator encoded by the ATN1 gene, which plays an important role in regulating gene expression through interactions with transcription factors, chromatin-modifying complexes, and nuclear regulatory proteins. Under normal physiological conditions, atrophin-1 contributes to transcriptional control during neuronal development and cellular differentiation by functioning as a scaffold protein that coordinates transcriptional activation and repression networks. The protein contains multiple functional domains, including an intrinsically disordered region and a polyglutamine (polyQ) tract encoded by CAG repeats, which are critical for its molecular interactions. Maintaining the balance between normal atrophin-1 activity and pathological alterations is essential, as abnormal ATN1 function can disrupt transcriptional homeostasis and contribute to neuronal vulnerability.

The major disease association of ATN1 is dentatorubral–pallidoluysian atrophy (DRPLA), a rare autosomal dominant neurodegenerative disorder caused by unstable expansion of CAG repeats within exon 5 of the ATN1 gene. The resulting polyglutamine-expanded atrophin-1 protein undergoes abnormal conformational changes, promotes toxic protein interactions, and interferes with transcriptional regulation in affected neurons. Patients with DRPLA typically develop progressive neurological symptoms, including cerebellar ataxia, myoclonus epilepsy, cognitive decline, psychiatric abnormalities, and movement disorders, reflecting degeneration of specific brain regions such as the dentate nucleus, red nucleus, globus pallidus, and related neural circuits. Current research indicates that polyQ-expanded atrophin-1 contributes to disease progression through multiple mechanisms, including altered transcriptional networks, impaired axonal transport, disrupted synaptic function, chromatin remodeling abnormalities, and activation of cellular stress responses.
Recent transcriptomic and molecular studies have further highlighted ATN1 as a key regulator of neuronal gene expression networks and a potential therapeutic target for polyglutamine disorders. Research using cellular models expressing pathogenic atrophin-1 has revealed widespread changes in pathways related to synaptic organization, extracellular matrix regulation, ion channel activity, neurodevelopment, inflammation, oxidative stress, and protein quality control, suggesting that ATN1 toxicity extends beyond simple protein aggregation. Understanding the normal biological functions of atrophin-1 and the molecular consequences of its polyQ expansion is critical for developing targeted strategies, including gene regulation approaches, protein homeostasis modulation, and neuroprotective therapies. For researchers investigating neurodegeneration, transcriptional dysregulation, and polyglutamine-associated diseases, ATN1 represents an important molecular target for uncovering disease mechanisms and advancing precision therapeutic development.
Alternate Names for ATN1
ATN1; atrophin 1; D12S755E,dentatorubral pallidoluysian atrophy (atrophin 1) , DRPLA; atrophin-1; B37; Dentatorubral-pallidoluysian atrophy protein; DRPLA; ATN1; Atrophin1; B37; D12S755E; HRS; NOD; dentatorubral-pallidoluysian atrophy protein; HRS; NOD; D
Loading ......